Wird geladen …
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
BACKGROUND: We have previously reported significantly longer overall survival (OS) with ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with advanced melanoma, with higher incidences of adverse events (AEs) at 10 mg/kg. This follow-up analysis reports a 5-year update of OS and safety. METH...
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Online Artikel Text |
Sprache: | English |
Veröffentlicht: |
BMJ Publishing Group
2020
|
Schlagworte: | |
Online Zugang: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279645/ https://www.ncbi.nlm.nih.gov/pubmed/32503946 http://dx.doi.org/10.1136/jitc-2019-000391 |